A recent study published in JAMA Network Open has explored the various factors influencing the initiation of semaglutide treatment among adults with obesity but without diabetes. Semaglutide, a GLP-1 receptor agonist initially approved for type 2 diabetes, has gained attention for its role in weight management and cardiovascular health. This surge in demand for the medication, particularly among individuals with obesity, raises important questions about accessibility and the socioeconomic determinants of healthcare.
Rising Popularity of Semaglutide
Originally prescribed for type 2 diabetes, semaglutide (marketed as Wegovy and Ozempic) has now been FDA-approved for weight management. As obesity has become a significant public health issue, especially in the U.S., the demand for effective weight loss medications has soared. Despite the availability of treatments like GLP-1 receptor agonists, many individuals with obesity remain undertreated, with lifestyle counseling often being the primary intervention recommended.
Obesity is a key risk factor for a variety of cardiometabolic conditions, including diabetes, yet the healthcare system still grapples with under-treatment, particularly in low-income communities and among people of color. Disparities in insurance coverage and access to medication further exacerbate these issues, limiting the reach of new, effective treatments.
Study Overview
The study aimed to uncover the factors influencing whether adults with obesity (but without diabetes) initiated semaglutide treatment. Researchers used a machine learning approach alongside multivariable regression modeling to identify key factors influencing medication initiation. Data was gathered from the Merative MarketScan Commercial Claims and Encounters database, which includes information from individuals aged 18 to 64 who were covered by commercial insurance between June 2020 and December 2022.
The cohort included individuals with at least one encounter with a healthcare provider related to obesity. Those with a history of bariatric surgery, antihyperglycemic medication use, or pregnancy within six months prior to the obesity diagnosis were excluded.
Key Findings
The study included 97,456 participants aged 45 to 54, with 50.7% covered by preferred provider organization (PPO) insurance plans. More than 50% of the cohort resided in the Southern U.S. Among this group, only about 2% were prescribed semaglutide within six months of their obesity diagnosis. The likelihood of receiving a prescription was higher among individuals aged 55 to 64 compared to younger adults (18-24 years).
Several factors influenced the likelihood of semaglutide initiation. Individuals with a higher body mass index (BMI) were more likely to receive the medication. Gender, socioeconomic status, age, geographic location, employment status, and insurance type were identified as key determinants. Women, older adults, those living in the Northeast and South, and individuals with PPO plans were more likely to start treatment with semaglutide. In contrast, those employed in unknown industries or with lower socioeconomic status had lower odds of initiating the medication.
Moreover, the study highlighted regional differences, with individuals in the North Central and Northeast regions more likely to initiate semaglutide than those in the West. Employment in specific sectors, such as non-durable goods manufacturing and finance, also correlated with higher rates of medication initiation.
Medications commonly prescribed for mental health conditions, such as amphetamines and antidepressants, were associated with a higher likelihood of initiating semaglutide, suggesting that some individuals may be using the drug as part of a broader treatment plan.
Conclusion
This study sheds light on the complex factors driving the initiation of semaglutide treatment among individuals with obesity but without diabetes. It identifies significant disparities in access to care and medication, which are often influenced by sociodemographic and economic factors. The findings also underscore the need for further research to explore the combined effects of commonly prescribed medications on the effectiveness of semaglutide and to better understand the impact of public insurance plans on treatment initiation.
Addressing these inequities will be essential to ensure that obesity treatment is accessible to all individuals, regardless of socioeconomic status or geographic location.
Related topics:
Surge in Demand for Diabetes Tech Strains New Zealand’s Health System
UVA Study Shows Continuous Glucose Monitors Can Predict Type 1 Diabetes Complications
Unlocking a New Era in Diabetes Care: Europe’s Call to Action
